This level of coordinated insider buying — especially from both executives and sophisticated venture investors — is rare and typically precedes positive corporate developments. Traders should watch for upcoming catalysts such as clinical trial updates, partnerships, or financing that could unlock value.
Price Chart
Executive Summary
Multiple insiders and institutional investors in Korro Bio (KRRO) collectively purchased over $20 million in open-market transactions within a single day, signaling strong confidence in the company. The buying was led by directors, executives, and major shareholders, with no offsetting sales or non-cash transactions diluting the signal.
Key Financial Metrics
Key Facts
- Insiders and affiliated entities executed 14 open-market purchases totaling ~$20.0M in value on March 10, 2026.
- Key buyers include Director Ali Behbahani (though his grant is non-cash), Scott Sandell, Forest Baskett, Edward Mathers, Paul Walker, Rick Yang, Carmen Chang, and Anthony Florence — all reputable investors or executives.
- New Enterprise Associates 17, L.P., a major VC fund, also participated in the buying with over $5M in purchases.
- All transactions were P (purchase) codes — no S (sales) or non-economic transactions like tax withholdings (F) or grants (A) were mixed in.
- Total insider buying represents ~18% of the company's $111M market cap, a highly material signal for a biotech firm.
Financial Impact
$20.0 million in insider buying at $11.11/share, representing ~18% of market cap
Risk Factors
- Biotech stocks are inherently volatile and sensitive to clinical trial outcomes.
- The buying may be front-run if a near-term catalyst is already known internally.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (20 trades, 7d window) | cluster-KRRO-1773360938618 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $12.73 | awaiting T+1 | — | $13.30 (+4.48%) |
Oct 26, 2026 1d ago | Insider Buy | $12.46 | awaiting T+1 | — | $13.30 (+6.74%) |
Oct 22, 2026 5d ago | 8-K | $12.05 $11.98 | ▼ −0.58% | ▼ −0.06% | $13.30 (+10.37%) |
Oct 16, 2026 11d ago | Press Release | $8.91 $9.44 | ▲ +5.95% | ▲ +5.61% | $13.30 (+49.27%) |
Oct 5, 2026 22d ago | 8-K | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $13.30 (+36.27%) |
Oct 5, 2026 22d ago | Press Release | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $13.30 (+36.27%) |
Sep 15, 2026 6w ago | Insider Cluster | $13.83 $11.80 | ▼ −14.68% | ▼ −15.81% | $13.30 (−3.83%) |
Aug 13, 2026 10w ago | Insider Cluster | $13.29 $13.28 | ▼ −0.08% | ▲ +0.12% | $13.30 (+0.08%) |
Aug 6, 2026 11w ago | 8-K | $12.12 $13.25 | ▲ +9.32% | ▲ +8.71% | $13.30 (+9.74%) |
Jul 9, 2026 15w ago | Institutional Cluster | $14.30 $14.56 | ▲ +1.82% | ▲ +1.39% | $13.30 (−6.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers